• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Shraga Rottem M.D., D.Sc., Expert, Author, Writer & External Scientific Relations on AI in Medical Applications

Shraga Rottem M.D., D.Sc.

Dr. Rottem is the co-inventor of the First High Frequency Transvaginal Probe (TVS) Nov. 1985, Technion, Israel. He established and directed the First TVS Clinic pioneering the use of TVS in the first trimester and in gynecology (1986-1991). The material of his TVS Clinic was the crucial source used to introduce TVS in the US, EU, and the rest of the world before immigrating to the US as Invited Expert (1992). He is also the co-author of the first book on Transvaginal Sonography (1987) and of a completely new TVS book in 1991. He introduced First Trimester Transient Nuchal Findings in Down Syndrome to Dr. Kypros Nicolaides of King’s College Hospital in London in 1988 (and reported it in the Lancet in 1989) and was Royal Society Guest Expert in First Trimester and Researcher to Prof. Stuart Campbell and Dr. Kypros Nicolaides (1991-1992). Dr. Rottem developed the diagnostic criteria of Ectopic Pregnancy and “Tubal Ring ” in PID in 1986 and the ultrasound lessons-based criteria used to diagnose Ovarian Cancer in 1989 and other pathologies used worldwide.

He is the co-founder of ISUOG and Ultrasound in ObGyn/UOG Journal and was previously the director of ObGyn Ultrasound and Assoc Professor of ObGyn at the State University of New York (1992-1998). He is the founder and director of Ironfan-International Registry of Fetal Anomalies since 1993, NY, USA, which was relocated to Columbia University Medical Center in 1999. The Ironfan is an International Multi-Center Research Network and Database for Early Prenatal Diagnosis and Acquisition of Data in a Network Environment. He developed the Time-Oriented Classification of the Natural History of Fetal Anomalies Based on Ultrasound with over 500 types of malformations. He is the guest editor of three full Special Journal Issues on TVS and in First Trimester with most of the content from his own research group: JCU, Journal of Ultrasound in Medicine and UOG. He has authored over 150 publications, peer review abstracts, and chapters in books, lectured in 29 countries and conducted many hands-on TVS courses worldwide. He serves as PI for the grants on three Early Prenatal Diagnosis projects, co-PI at an Ovarian Cancer project and the co-PI at a Medical AI based system for DoD (Department of Defense, USA).

Dr. Rotten is also the founder and director of the First Artificial Intelligence in Fetal Medicine and Machine Learning Institute developed at the Audubon Biomedical Research Center of Columbia University Medical Center (project started in 2014). He is recognized as the inventor of The AI Based Early Screening System for Fetal CHDs and of CDS of Neonatal CHDs for remote hospitals and developing world, and of the AI based Automatic Error Reduction when Screening for CHDs and diagnosing other problems in pregnancy and of an In Silico Based Early Diagnostic System (diagnoses not existing otherwise). Additionally, he invented an intelligent system shortening the development of new drugs and of the length of FDA trials. He is the inventor of two biosensors and AI in Oncology and in another specialty. He has authored eight patents (three issued) and founded and financed three medical AI companies with over $6m from SBA, DoD, a Research Foundation and other sources.

Presentation: AI in Fetal Medicine

EDUCATION

M.D., State University of Milan, Milan, Italy

D.Sc., Technion, IIT, Haifa, Israel

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 1,254 other subscribers
  • Recent Posts

    • Press Release for Five Bilingual BioMed e-Series January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
    • Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
    • Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
    • Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
    • Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
    • Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
    • The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
    • Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: